FierceBiotech November 25, 2025

<a href="https://www.fiercebiotech.com/biotech/pfizer-details-phase-3-data-mrna-flu-vaccine" hreflang="en">Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3</a>

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.